glycopyrrolate

Summary

Summary: A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.

Top Publications

  1. Paton F, Paulden M, Chambers D, Heirs M, Duffy S, Hunter J, et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010;105:558-67 pubmed publisher
    ..We performed a systematic review of randomized controlled trials of sugammadex compared with neostigmine/glycopyrrolate and an economic assessment of sugammadex for the reversal of moderate or profound neuromuscular block (NMB) ..
  2. Cober M, Johnson C, Sudekum D, Penprase K. Stability of extemporaneously prepared glycopyrrolate oral suspensions. Am J Health Syst Pharm. 2011;68:843-5 pubmed publisher
    The stability of extemporaneously prepared glycopyrrolate 0.5-mg/mL suspensions was evaluated.
  3. Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011;105:337-42 pubmed publisher
    ..NVA237 was well tolerated; all adverse events were mild or moderate in intensity and not related to study drug. NVA237 50 ?g once daily was well tolerated and showed significant and sustained 24-h bronchodilation in patients with COPD...
  4. Van de Maele B, Fabbri L, Martin C, Horton R, Dolker M, Overend T. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD. 2010;7:418-27 pubmed publisher
    ..Once-daily QVA149 was well tolerated in COPD patients with a cardiovascular safety profile and overall adverse event rates similar to placebo...
  5. Sacan O, White P, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569-74 pubmed
    ..We tested the hypothesis that sugammadex would provide for a more rapid reversal of a moderately profound residual rocuronium-induced blockade than the commonly used cholinesterase inhibitors, edrophonium and neostigmine...
  6. Garnock Jones K. Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions. Paediatr Drugs. 2012;14:263-9 pubmed publisher
    ..b>Glycopyrrolate oral solution, an anticholinergic agent, is the first drug treatment approved in the US for drooling in ..
  7. van Noord J, Buhl R, LaForce C, Martin C, Jones F, Dolker M, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010;65:1086-91 pubmed publisher
  8. Duggal H. Glycopyrrolate for clozapine-induced sialorrhea. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1546-7 pubmed
  9. Herbstreit F, Zigrahn D, Ochterbeck C, Peters J, Eikermann M. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2010;113:1280-8 pubmed publisher
    ..However, neostigmine may also impair muscle strength. We hypothesized that neostigmine administered after recovery of the train-of-four (TOF) ratio impairs upper airway integrity and genioglossus muscle function...

More Information

Publications62

  1. Hansel T, Neighbour H, Erin E, Tan A, Tennant R, Maus J, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005;128:1974-9 pubmed
    ..Racemic glycopyrrolate is an anticholinergic drug that has been used orally to control gastric acidity, parenterally as an ..
  2. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan V, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40:1106-14 pubmed publisher
    ..NVA237 can potentially be an alternative choice of LAMA for COPD patients...
  3. Beeh K, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-13 pubmed publisher
    ..We assessed the effects of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on exercise tolerance in patients with moderate to severe COPD...
  4. Sechaud R, Renard D, Zhang Auberson L, Motte S, Drollmann A, Kaiser G. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50:118-28 pubmed
    ..This study investigated the pharmacokinetics (PK) of NVA237 following single and repeated once-daily inhalation in mild-tomoderate COPD patients...
  5. Goldstein D, Pechnik S, Moak J, Eldadah B. Painful sweating. Neurology. 2004;63:1471-5 pubmed
    ..The authors report a case of spontaneous and gustatory facial pain and sweating...
  6. Kim W, Kil H, Yoon D, Cho M. Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate. Yonsei Med J. 2003;44:579-82 pubmed
    ..Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic ..
  7. Lund N, Maxel T, Rungby J. [Successful treatment of diabetic gustatory hyperhidrosis with topical glycopyrrolate]. Ugeskr Laeger. 2011;173:2200-1 pubmed
    ..In this case a patient with diabetes suffering from gustatory hyperhidrosis was treated successfully with topical glycopyrrolate, an anticholinergic agent applied directly on the affected area.
  8. D Urzo A, Ferguson G, van Noord J, Hirata K, Martin C, Horton R, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156 pubmed publisher
    ..The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD...
  9. Dahl R, Chapman K, Rudolf M, Mehta R, Kho P, Alagappan V, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107:1558-67 pubmed publisher
    ..We investigated the safety and efficacy of QVA149 over 52 weeks...
  10. Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J. 1996;9:100-3 pubmed
    We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD)...
  11. Ledowski T, Preuss J, Schug S. The effects of neostigmine and glycopyrrolate on skin conductance as a measure of pain. Eur J Anaesthesiol. 2009;26:777-81 pubmed publisher
    ..In this context, the effects of cholinesterase inhibitors and anticholinergic drugs used for the reversal of muscle relaxants were investigated...
  12. Vogelmeier C, Banerji D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2011;5:163-73 pubmed publisher
    ..Phase III studies are ongoing that will assess the long-term safety and efficacy of NVA237...
  13. Liang C, Ho P, Shen L, Lee W, Yang F, Chiang K. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res. 2010;119:138-44 pubmed publisher
    ..Previous case reports have suggested the benefit of glycopyrrolate or biperiden in treating this condition, but no randomized controlled trial has provided evidence...
  14. Villetti G, Bergamaschi M, Bassani F, Bolzoni P, Harrison S, Gigli P, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148:291-8 pubmed
    1. Our study was aimed at investigating the duration of the bronchodilator action of the antimuscarinc drug glycopyrrolate compared to tiotropium and ipratropium...
  15. Walling H. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol. 2012;66:387-92 pubmed publisher
    ..Data regarding systemic medications in the management of hyperhidrosis (HH) are limited...
  16. Mier R, Bachrach S, Lakin R, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med. 2000;154:1214-8 pubmed
    To determine the safety and efficacy of glycopyrrolate in the treatment of developmentally disabled children with sialorrhea.
  17. Bateman E, Ferguson G, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-94 pubmed publisher
  18. Seifert T, Fisher J, Young C, Hartwich D, Ogoh S, Raven P, et al. Glycopyrrolate abolishes the exercise-induced increase in cerebral perfusion in humans. Exp Physiol. 2010;95:1016-25 pubmed publisher
    ..were performed in control (no drug) conditions and following muscarinic cholinergic receptor blockade by glycopyrrolate. Glycopyrrolate increased resting heart rate from approximately 60 to approximately 110 beats min(-1) (P < ..
  19. Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010;104:1482-9 pubmed publisher
    ..All doses of NVA237 and tiotropium were well tolerated. NVA237 once-daily was effective and well tolerated versus placebo, and demonstrated rapid and sustained 24-h bronchodilation. (ClinicalTrials.gov Identifier: NCT00501852)...
  20. Vogelmeier C, Verkindre C, Cheung D, Galdiz J, Güçlü S, Spangenthal S, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010;23:438-44 pubmed publisher
    ..Overall, the present study provides further evidence of the safety, tolerability and bronchodilator efficacy of once-daily treatment with NVA237 100 and 200 microg in patients with moderate-to-severe COPD...
  21. Arbouw M, Movig K, Koopmann M, Poels P, Guchelaar H, Egberts T, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010;74:1203-7 pubmed publisher
    ..Sialorrhea is often treated with anticholinergics, but central side effects limit their usefulness. Glycopyrrolate (glycopyrronium bromide) is an anticholinergic drug with a quaternary ammonium structure not able to cross the ..
  22. Malik J, Gupta D, Agarwal A, Jindal S. Anticholinergic premedication for flexible bronchoscopy: a randomized, double-blind, placebo-controlled study of atropine and glycopyrrolate. Chest. 2009;136:347-354 pubmed publisher
    ..Anticholinergic premedication is commonly used during flexible bronchoscopy, although the benefits are unproven and potential risks exist...
  23. Benson G, Thurmon J, Tranquilli W, Corbin J. Intravenous administration of lenperone and glycopyrrolate followed by continuous infusion of sufentanil in dogs: cardiovascular effects. Am J Vet Res. 1987;48:1372-5 pubmed
    Cardiopulmonary effects of IV administration of lenperone (0.44 mg/kg) and glycopyrrolate (0.11 mg/kg) were determined in 6 healthy adult (2 to 5 years) Pointers during controlled ventilation with oxygen...
  24. Rabe K. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Rev Clin Pharmacol. 2017;10:685-698 pubmed publisher
    ..Areas covered: This article describes the rationale for the development of the LAMA/LABA FDC of glycopyrrolate and formoterol fumarate, formulated by Co-Suspension™ Delivery Technology and delivered by MDI (GFF MDI)...
  25. Ghezzi E, Ship J. Aging and secretory reserve capacity of major salivary glands. J Dent Res. 2003;82:844-8 pubmed
    ..crossover study was to determine age-related differences in salivary response to an anti-sialogogue (glycopyrrolate). Thirty-six healthy subjects (18 young--20-38 yrs; 18 older--60-77 yrs) received 4.0 microg/kg i.v...
  26. Panting K, Alkali A, Newman W, Sharpe G. Dilated pupils caused by topical glycopyrrolate for hyperhidrosis. Br J Dermatol. 2008;158:187-8 pubmed
  27. Lenz A, Hill G, White P. Emergency use of sugammadex after failure of standard reversal drugs. Anesth Analg. 2007;104:585-6 pubmed
    ..42-yr-old patient with chronic renal failure who had received vecuronium, 10 mg IV, for tracheal intubation, after inadequate reversal of neuromuscular blockade in the operating room with neostigmine, 5 mg IV, and glycopyrrolate, 1 mg IV.
  28. Storme M, t Kindt R, Goeteyn W, Reyntjens K, Van Bocxlaer J. Quantitative determination of glycopyrrolate in human plasma by liquid chromatography-electrospray ionization mass spectrometry: the use of a volatile ion-pairing agent during both liquid-liquid extraction and liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876:24-30 pubmed publisher
    ..with the development of a quantitative tool for the determination of the quaternary ammonium anticholinergic glycopyrrolate in human plasma samples. Mepenzolate was used as an internal standard...
  29. Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012;11:CD008624 pubmed publisher
    ..A range of interventions exist that aim to reduce or eliminate drooling. There is a lack of consensus regarding which interventions are most effective for children with CP...
  30. Rao T, Sakaguchi N, Juneja L, Wada E, Yokozawa T. Amla (Emblica officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. J Med Food. 2005;8:362-8 pubmed
    ..Amla also significantly improved the serum adiponectin levels. These results form the scientific basis supporting the efficacy of amla for relieving the oxidative stress and improving glucose metabolism in diabetes...
  31. Roh J, Kim H, Kim A. The effect of acute xerostomia on vocal function. Arch Otolaryngol Head Neck Surg. 2006;132:542-6 pubmed
    ..To evaluate whether xerostomia can affect vocal function in an experimental model...
  32. Roach D, Thakore E, Sheldon R. Origins of heart rate variability: autonomic blockade of large magnitude, transient bradycardia in conscious rabbits. Can J Cardiol. 2001;17:185-91 pubmed
    ..One such structure is a large magnitude transient bradycardia (LMTB), which resembles published reports of responses to alerting stimuli. Alerting responses are sensitive to alpha1-adrenoceptor and cholinergic receptor blockade...
  33. Patel P, Ghezzi E, Ship J. Xerostomic complaints induced by an anti-sialogogue in healthy young vs. older adults. Spec Care Dentist. 2001;21:176-81 pubmed
    ..medications are known to inhibit salivation, this study attempted to determine if an anticholinergic drug (glycopyrrolate) had a differential effect on xerostomic complaints in young vs. older adults...
  34. Wedzicha J, Banerji D, Chapman K, Vestbo J, Roche N, Ayers R, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-34 pubmed publisher
    ..The role of treatment with a LABA-LAMA regimen in these patients is unclear...
  35. Raghavendran S, Brown K, Buu N. Perioperative management of patients with Cockayne syndrome - recognition of accelerated aging with growth arrest. Paediatr Anaesth. 2008;18:360-1 pubmed publisher
  36. Shah S, Sangari T, Qasim M, Martin T. Severe hypertension and bradycardia after dexmedetomidine for radiology sedation in a patient with acute transverse myelitis. Paediatr Anaesth. 2008;18:681-2 pubmed publisher
  37. Wilkins B, Hesse C, Sviggum H, Nicholson W, Moyer T, Joyner M, et al. Alternative to ganglionic blockade with anticholinergic and alpha-2 receptor agents. Clin Auton Res. 2007;17:77-84 pubmed
    ..baroreflex-mediated cardiovascular responses during the administration of a muscarinic receptor antagonist (glycopyrrolate; GLY: ) and a selective alpha-2 receptor agonist (dexmedetomidine; DEX: ) and to compare responses to ..
  38. Toksvang L, Plovsing R. Symptoms of Central Anticholinergic Syndrome After Glycopyrrolate Administration in a 5-Year-Old Child. A A Case Rep. 2016;6:22-4 pubmed publisher
    ..syndrome (CAS) is most commonly associated with administration of atropine or scopolamine, whereas glycopyrrolate is an extremely rare cause of CAS...
  39. Sinclair M, O Grady M, Kerr C, McDonell W. The echocardiographic effects of romifidine in dogs with and without prior or concurrent administration of glycopyrrolate. Vet Anaesth Analg. 2003;30:211-9 pubmed
    To determine the cardiopulmonary response to romifidine (RO) in the dog with or without prior or concurrent administration of glycopyrrolate.
  40. Cowl C, Prakash U, Kruger B. The role of anticholinergics in bronchoscopy. A randomized clinical trial. Chest. 2000;118:188-92 pubmed
  41. Wray D, Formes K, Weiss M, O Yurvati A, Raven P, Zhang R, et al. Vagal cardiac function and arterial blood pressure stability. Am J Physiol Heart Circ Physiol. 2001;281:H1870-80 pubmed
    ..the importance of vagal cardiac modulation in arterial blood pressure (ABP) stability before and after glycopyrrolate or atropine treatment. Changes in R-R interval (RRI) and ABP were assessed in 10 healthy young (age, 22 +/- 1...
  42. Drollmann A, Sechaud R, Pal P, Hara H, Uziel Fusi S, Winkle P. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study. Int J Clin Pharmacol Ther. 2014;52:739-45 pubmed publisher
    ..This study evaluated the effect of glycopyrronium on the QT interval and other cardiac parameters in healthy subjects...
  43. Urman J, Bobrove A. Diabetic gustatory sweating successfully treated with topical glycopyrrolate: report of a case and review of the literature. Arch Intern Med. 1999;159:877-8 pubmed
    ..Gustatory sweating is a more common manifestation of diabetes mellitus than is appreciated. It is a distressing problem that has been difficult to treat safely...
  44. Ladjevic N, Likic Ladjevic I. Topical glycopirrolate for the management of hyperhidrosis in herpetic neuralgia. Yonsei Med J. 2009;50:293-5 pubmed publisher
    ..During the Glycopirrolate cream therapy, there were no side effects. This is a first report to document that a topical Glycopirrolate cream has a beneficial effect in a patient with hyperhidrosis and herpetic neuralgia...
  45. Chisakuta A, Mirakhur R. Anticholinergic prophylaxis does not prevent emesis following strabismus surgery in children. Paediatr Anaesth. 1995;5:97-100 pubmed
    ..The children were allocated to three groups, to receive placebo (n = 40), glycopyrrolate (n = 40) or atropine (n = 41)...
  46. Ulrik C. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012;7:673-8 pubmed publisher
    ..The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD...
  47. Lester P, Gaynor J, Hellyer P, Mama K, Wagner A. The sedative and behavioral effects of nalbuphine in dogs. Contemp Top Lab Anim Sci. 2003;42:27-31 pubmed
    ..05 mg/kg acepromazine s.c. Group A received 0.05 mg/kg acepromazine s.c. All dogs received 0.01 mg/kg glycopyrrolate s.c. All doses were administered preoperatively...
  48. Alijani A, Hanna G, Band M, Struthers A, Cuschieri A. Cardiovascular autonomic function in patients with hemodynamic instability at induction of capnoperitoneum: a case-control study. Surg Endosc. 2004;18:915-8 pubmed
    ..This study hypothesized that patients in whom bradycardia and hypotension develop with induction of positive-pressure capnoperitoneum have an underlying autonomic cardiovascular dysfunction...
  49. Hamner J, Tan C, Tzeng Y, Taylor J. Cholinergic control of the cerebral vasculature in humans. J Physiol. 2012;590:6343-52 pubmed publisher
    ..03 to 0.08 Hz in nine healthy subjects with and without cholinergic blockade via glycopyrrolate. Cholinergic blockade increased cross-spectral coherence between arterial pressure and cerebral flow at all ..
  50. Osipova D, Ahveninen J, Kaakkola S, Jaaskelainen I, Huttunen J, Pekkonen E. Effects of scopolamine on MEG spectral power and coherence in elderly subjects. Clin Neurophysiol. 2003;114:1902-7 pubmed
    ..In order to test the sensitivity of spectral power and hemispheric coherence to changes in cholinergic transmission, we evaluated quantitative magnetoencephalogram (MEG) after intravenous injection of scopolamine...
  51. Hugel H, Ellershaw J, Gambles M. Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med. 2006;9:279-84 pubmed
  52. Rasmussen P, Andersson J, Koch P, Secher N, Quistorff B. Glycopyrrolate prevents extreme bradycardia and cerebral deoxygenation during electroconvulsive therapy. J ECT. 2007;23:147-52 pubmed
    ..effect of this bradycardia on cerebral perfusion and oxygenation by administration of the anticholinergic drug glycopyrrolate (Glp)...
  53. Syed T, Tamis Holland J, Coven D, Hong M. Can glycopyrrolate replace temporary pacemaker and atropine in patients at high risk for symptomatic bradycardia undergoing AngioJet mechanical thrombectomy?. J Invasive Cardiol. 2008;20:19A-21A pubmed
    We studied the feasibility and efficacy of glycopyrrolate, a synthetic anticholinergic agent with shorter half-life and without reflex tachycardia, in preventing symptomatic bradycardia in patients undergoing mechanical thrombectomy with ..